Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

36.94 +0.12 (+0.33%)

Streaming Delayed Price Updated: 12:04 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer ↗

Today 9:16 EDT

The company recently obtained approval for a higher-dose version of Wegovy.

Via The Motley Fool

Institutional Titans Bet Big on Amgen as Dividend Yield Hits 2.9% Benchmark

March 23, 2026

In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026....

Via MarketMinute

Topics ETFs Earnings

Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? ↗

March 22, 2026

One of these assets is catalyst-driven; the other isn't.

Via The Motley Fool

Topics Intellectual Property

Should You Buy Eli Lilly Stock Before April 10? ↗

March 22, 2026

A catalyst for stock performance may be just ahead.

Via The Motley Fool

Is This Stock a Buy on the Dip? ↗

March 21, 2026

This company has a habit of beating the market over long periods.

Via The Motley Fool

This Hims & Hers Move Could Destroy Competitors ↗

March 21, 2026

The Wegovy pill could change Hims & Hers' growth in 2026.

Via The Motley Fool

Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up? ↗

March 20, 2026

The healthcare stock has lost more than half of its value in the past year.

Via The Motley Fool

Is It Too Late to Buy Eli Lilly? ↗

March 19, 2026

Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact.

Via The Motley Fool

Topics Intellectual Property

1 Reason I'm Never Selling Novo Nordisk Stock ↗

March 19, 2026

I am not turned off by the company's recent setbacks.

Via The Motley Fool

Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot

March 18, 2026

As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year...

Via Finterra

Topics Intellectual Property

Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk ↗

March 18, 2026

The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform.

Via Stocktwits

The Best Healthcare Stocks to Buy With $50 Right Now ↗

March 18, 2026

Even on a budget, you can get quality stocks.

Via The Motley Fool

Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics ↗

March 17, 2026

Each of these companies could benefit from this high-growth market over time.

Via The Motley Fool

Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move ↗

March 17, 2026

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

Via The Motley Fool

Topics Stocks

LLY Shares Dive On Analyst Downgrade Citing Obesity Market Overestimation Concerns, But Retail Dismisses ‘Absurd’ Selloff ↗

March 17, 2026

The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday.

Via Stocktwits

Why Eli Lilly Stock Just Dropped ↗

March 17, 2026

Eli Lilly's stock price is based on growth rates that might fall short.

Via The Motley Fool

This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock ↗

March 17, 2026

Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.

Via The Motley Fool

Should You Avoid Pfizer? Here's the Key Risk to Watch ↗

March 17, 2026

Pfizer has reached a turning point.

Via The Motley Fool

Topics Intellectual Property

Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗

March 16, 2026

The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.

Via The Motley Fool

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand ↗

March 15, 2026

Via MarketBeat

MarketBeat Week in Review – 03/09 - 03/13 ↗

March 14, 2026

Despite continued volatility, stocks have stayed resilient as investors navigate the fog of war. The story is largely about oil. When the price of crude oil goes up, stocks go down and vice versa....

Via MarketBeat

Is Eli Lilly's Weight Loss Empire in Trouble? ↗

March 13, 2026

It won't be easy to knock the company off its pedestal.

Via The Motley Fool

3 Dirt-Cheap Stocks to Buy With $1,000 Right Now ↗

March 13, 2026

As the old adage goes, cheap stocks are cheap for a reason. But the reason might not be a good one.

Via The Motley Fool

Topics Earnings

The Real Reason Eli Lilly Is Pouring $3 Billion Into China ↗

March 13, 2026

Via MarketBeat

The Great Pivot: How the Novo Nordisk Deal Transformed Hims & Hers (HIMS) into a Healthcare Powerhouse

March 13, 2026

As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from...

Via Finterra

Topics Economy

Does This Deal Make Novo Nordisk Stock a Buy? ↗

March 12, 2026

Not many things have gone right for Novo Nordisk recently, but this is one of them.

Via The Motley Fool

Topics Intellectual Property Lawsuit

The New Era of Hims & Hers Health (HIMS): Navigating the Branded Obesity Drug Pivot

March 12, 2026

As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers...

Via Finterra

Forget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner ↗

March 11, 2026

A new battle between these longtime rival companies will likely go the same way as their previous battles.

Via The Motley Fool

Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War

March 11, 2026

The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant...

Via MarketMinute

Topics Economy Intellectual Property Lawsuit

The Greenland Ultimatum: Trump Weaponizes Tariffs in Bid for the Arctic's 'Crown Jewel'

March 11, 2026

The global trade landscape was thrown into a state of high-stakes volatility this quarter as President Trump issued a stark ultimatum to America’s closest European allies: enter negotiations for the...

Via MarketMinute

Topics Economy Electric Vehicles Government

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today